Primary WWOX phosphorylation and JNK activation during etoposide induces cytotoxicity in HEK293 cells by Jamshidiha, M. et al.
Primary WWOX phosphorylation and JNK activation during etoposide 
induces cytotoxicity in HEK293 cells
1,2Jamshidiha M., 3Habibollahi P., 1Ostad S.N., *1,2,3Ghahremani M.H.
1Department of Pharmacology-Toxicology, Faculty of Pharmacy, 2Pharmaceutical Science 
Research Centre, 3Department of Molecular Medicine, School of Advanced Medical 
Technologies, Tehran University of Medical Sciences, Tehran, Iran.
Received 18 Nov 2009; Revised 10 March 2010; Accepted 30 March 2010
ABSTRACT
Background and the purpose of the study: Etoposide is an antineoplastic agent used in multiple 
cancers. It is known that etoposide induce cell death via interaction with topoisomerase II; 
however,  the  etopoisde  cellular  response  is  poorly  understood.  Upon  etoposide  induced 
DNA damage, many stress signaling pathways including JNK are activated. In response to 
DNA damage, it has been shown that WWOX, a recently introduced tumor suppressor, can 
be activated. In this study the activation of WWOX and JNK and their interaction following 
etoposide treatment were evaluated.
Materials and Methods: HEK293 cells treated with etoposide were lysed in a time course 
manner. The whole cell lysates were used to evaluate JNK and WWOX activation pattern using 
Phospho specific antibodies on western blots. The viability of cells treated with etoposide, JNK 
specific inhibitor and their combination was examined using MTT assay.
Results: Findings of this study indicate that WWOX and JNK are activated in a simultaneous 
way  in  response  to  DNA  damage.  Moreover,  JNK  inhibition  enhances  etoposide  induced 
cytotoxicity in HEK293. 
Conclusion: Taken together, our results indicate that etoposide induces cytotoxicity and WWOX 
phosphorylation and the cytotoxicty is augmented by blocking JNK pathway.
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INTRODUCTION
Etoposide  is  an  antineoplastic  agent  with  known 
inhibition of topoisomerase II property which has 
been  demonstrated  to  have  antineoplastic  activity 
in  multiple  cancers  (1)    such  as  acute  myeloid 
leukemia (AML), Hodgkins disease, non hodgkins 
lymphoma, lung cancer (2), gastric cancer, breast 
(3) and ovarian cancer (4). Although it is known that 
etoposide induces cell death via DNA damage due 
to interaction with topoisomerase II (5), it’s cellular 
response is poorly understood. 
Following etoposide induced DNA damage, various 
cellular  pathways  including  mitogen  activated 
protein kinase (MAPK) are activated (6). The c-jun 
N-terminal kinase (JNK) is a MAPK which can be 
activated in response to inflammation, stress, heat 
shock, UV and growth factors (7, 8). It is shown that 
JNK has a dual role in cell differentiation and cell 
death although the exact mechanism is unknown. 
Three genes encode JNK1, JNK2, JNK3 isoforms 
with  85%  identity  among  these  enzymes.  While 
JNK1  and  JNK2  are  distributed  in  most  tissues, 
JNK3 is only present in the CNS (9) . 
WWOX,  an  oxidoreductase  protein,  is  a  tumor 
suppressor protein and its defect has been identified 
in  multiple  malignancies  such  as  prostate  (10), 
breast (11), lung (12) and gastric cancer (13). It is 
known that WWOX mediates its effect in response 
to DNA damage, UV irradiation and staurosporine 
via increasing p53 stability (7) . When WWOX is 
transiently transfected, 95% of cells died within 3 
days.  Furthermore,  cells  transfected  with  siRNA 
targeted  to  WWOX  show  increase  tolerance 
in  response  to  DNA  damage  (14)  and  JNK 
overexpression inhibits WWOX induced cell death 
(15). Thus, there is a signaling link between JNK 
and WWOX with regard to the cell death. 
Moreover,  the  tolerance  during  cancer  therapy 
results in treatment failure or adverse effects and 
combination  therapy  is  an  effective  strategy  to 
avoid drug resistance. Identification of new targets 
or  pathways  activated  via  etoposide  gives  clues 
for  new  combinational  therapies.  In  addition, 
primary  resistance  to  etoposide  in  many  patients 
has been reported and understanding the alteration 
in downstream pathways activated by etoposide will 
provide new therapeutic approaches.  In this study 
the time course of JNK and WWOX activation in 
141buffer saline (PBS), total lysate was prepared using 
protein lysis buffer (Tris 62.5 mM, pH 6.8, DTT 
50 mM, SDS 10%, glycerol 10% and bromophenol 
blue 0.25%(w/v)) and stored at -80ºC. Equal amount 
of  samples  were  subjected  to  10%  SDS–  PAGE. 
The gels were then blotted onto PVDF membrane 
and blocked with 1% casein, 0.05% Tween 20 in 
TBS at 4ºC for 4–6 hrs. The membrane was probed 
with the 1:1000 dilution of primary antibodies. The 
membranes then probed with corresponding HRP-
conjugated secondary antibody at a 1:10,000 dilution. 
Signals were visualized using chemiluminescence on 
Biomax film. Densitometry analysis was performed 
using Scion Image (Ver. 4.0.2; Scion corporation, 
USA). The signals obtained for each protein were 
normalized  to  β-actin  and  Mean  ±  SE  of  three 
independent experiments were plotted (16) .
Determination  of  mitochondrial  dehyrogenase 
activity (MTT)
After  drug  treatments,  cells  were  incubated  with 
MTT  (1mg/ml)  for  4  hrs  at  37ºC.  Mitochondrial 
dehyrogenases of viable cells cleave the tetrazolium 
ring of the yellow MTT to yield purple formazan 
crystals which are insoluble in aqueous solutions. 
The  crystals  were  dissolved  in  100  µl  of  DMSO 
and the absorbance of the resulting purple solution 
was measured at 570 nm against 690 nm for blank 
solution.  The  amount  of  produced  formazan  is 
directly proportional to the number of viable cells.
Statistical analysis
The results were analyzed using one way ANOVA 
followed by Tukey-Kramer post test. The p value 
less than 0.05 (p<0.05) was considered significant. 
RESULTS
Effect of etoposide on HEK293 viability
Results of this study indicate that etoposide reduce 
cell viability at 50 µM by 10%. The cytotoxicity 
increases to 75% at 200 µM and IC50 of this effect 
is  about  150  µM  (Figure  1).  For  combination 
treatments,  100  µM  of  etoposide  was  used  to 
observe the synergistic effect better since viability 
is very low at high doses of etoposide and can mask 
the synergistic effect.
Effect of etoposide on JNK activation
Results also indicate that HEK293 cells have low 
level of Phospho-JNK in normal conditions. After 
treatment  with  etoposide,  Phospho  JNK  level 
increased  to  3  folds  of  control  level  (zero  time) 
within 30 min and maintained high during exposure 
to etoposide (Figure 2). Total JNK expression did 
not change (data not shown).
Effect of etoposide on WWOX activation
Results  obtained  from  Phospho-WWOX  indicate 
HEK293 cells following etoposide treatment were 
evaluted. In addition, the viability of the cells treated 
with etoposide alone or in combination with JNK 
specific inhibitor was examined.
MATERIAL  AND  METHODS
Chemicals
(3-[4,5-dimethyl thiazol-2yl]- 2,5 diphenyl tetrazolium 
bromide (MTT), etoposide and SP600125 were from 
Sigma  (UK);  Dithiothreitol  (DTT),  Western  blot 
detection kit and polyvinylidene fluoride (PVDF) were 
purchased  from  Roche  applied  science  (Germany). 
Phospho-JNK,  β-actin  antibodies  were  from  Cell 
Signaling  Technology  (USA);  Phospho-WWOX 
antibody was from abcam (UK), RPMI-1640, Fetal 
Bovine Serum (FBS), penicillin-streptomycin, trypsin-
EDTA were purchased from Gibco (UK). Biomax film 
was obtained from Kodak (UK). All other chemicals 
were from Merck (Germany).
Cell culture 
Human  embryonic  kidney  cells  (HEK  293  cells) 
were obtained from Cell bank of Pasteur Institute of 
Iran, cultured in RPMI-1640 containing 10% FBS, 
1%  penicillin-streptomycin  and  maintained  in  a 
humidified atmosphere of 5% CO2 at 37ºC. Cells 
were plated at 106 in 35 mm tissue culture dishes 
(for protein extraction) or 104 in 96 well plate (for 
MTT assay) for 24 hrs and treated with 100µM 
etoposide.  Cells  were  plated  triplicates  for  each 
treatment group.
Western blot
At various time points, cells were lysed for SDS–
PAGE  and  immunoblotting  experiments.  Prior  to 
lysis,  cells  were  rinsed  with  ice-cold  phosphate 
Fig.1
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Figure 1. Effect of etoposide on HEK293 cell viability. Cells 
were seeded at 104 in 96-well plates and treated with etoposide 
(50,100,150 and 200µM) for 24 hrs and compared to nontreated 
cells (control). At the end of treatment period, cell viability was 
measured using MTT assay. OD570 were measured and the results 
were presented as Mean ± SD (n=6).
 Etoposide induced WWOX and JNK phosphorylation 142that HEK293 cell line has a low level of Phospho-
WWOX during normal culture. After treatment with 
etoposide, Phospho-WWOX increased significantly 
and reached to 4 fold of zero time and this level 
was  maintained  during  exposure  to  etoposide 
(Figure 3).
Effect of etoposide and JNK inhibition on viability 
of HEK cells
Figure 3 indicates the viability of cells treated with 
etoposide  (100  µM),  SP600125  (20  µM,  specific 
JNK inhibitor) and combination of SP600125 and 
etoposide. As results show, etoposide and SP600125 
lowered HEK cell viability after 24 hrs. However, 
this  effect  was  not  statistically  significant  from 
untreated  cells  (control).  Interestingly,  cells  pre-
treated with JNK specific inhibitor and exposed to 
etoposide  showed  a  marked  decrease  in  viability 
by 50% (Figure 4), suggesting a significant role for 
JNK function in etoposide induced cell death.
DISCUSSION
Although DNA damage is the cause of etoposide 
induced cell death, many pathways are involved in 
executing cell death. JNK and recently introduced 
tumor suppressor, WWOX, are proteins that their 
role to DNA damage has been studied extensively 
in response (17). Recent studies have shown that 
cells containing specific mutant forms of WWOX 
don’t respond to DNA damage induced cell death 
(18). Furthermore, it is known that p53 is activated 
in response to DNA damage and WWOX siRNA 
Fig.2
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Figure 3. The time course of WWOX phosphorylation following 
exposure to etoposide in HEK 293 cells. Cells were plated 106 in 
35 mm dishes and exposed to etoposide 100µM. Total cell lysate 
was prepared at 0, 30, 60, 120, 180 and 240 min and subjected 
to SDS–PAGE. A: The bands for phospho-WWOX and β-Actin 
were detected by specific antibodies. B: The densitometry analysis 
performed and data presented as Mean ± SD of three independent 
experiments (n=3).
Figure 2. The time course of JNK phosphorylation following 
exposure to etoposide  in HEK 293 cells. Cells were plated 106 in 
35 mm dishes and exposed to etoposide 100µM. Total cell lysate 
was prepared at 0, 30, 60, 120, 180 and 240 min and subjected to 
SDS–PAGE. A: The bands for phospho-JNK and β-Actin were 
detected  by  specific  antibodies.  B: The  densitometry  analysis 
performed and data presented as Mean ± SD of three independent 
experiments (n=3).
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Figure  4.  Effect  of  JNK  inhibition  on  etoposide  induced 
cytotoxicity. Cells were seeded at 104 in 96-well plates and treated 
with etoposide (100µM) or SP600125 (20 µM) for 24 hrs .The 
pretreated group (E+SP) received SP600125 for 2 hrs and then 
treated with etoposide for another 24 hrs. At the end of treatment 
period, cell viability was measured using MTT assay. OD570 were 
measured and the results were presented as Mean ± SD (n=6). The 
data were analyzed using One way ANOVA followed by tukey 
post test (** p<0.01 compared to control).
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Jamshidiha et al / DARU 2010 18 (2) 141 -145 143inhibits  p53  dependent  cell  death  (14).  Thus, 
cancer  cells  with  defect  in  their  WWOX  gene 
would probably resist to etoposide chemotherapy. 
Results of this study indicate that etoposide quickly 
activates  JNK  and  WWOX  and  the  levels  of 
phospho-JNK  and  phospho-WWOX  remain  high 
throughout the exposure. In addition our findings 
show  that  the  inhibition  of  JNK  synergistically 
enhances  cytotoxicity  of  etoposide.  Therefore, 
WWOX activation and block of JNK function could 
have similar effects to exert cell death and could 
bring  up  new  strategies  in  specific  cancers  such 
as small cell lung cancer. Furthermore, our results 
indicate that etoposide can increase active form of 
JNK. Although, it seems that this effect is opposing 
the cytotoxic outcome of etoposide treatment, it is 
known  that  various  transcription  factors  such  as 
c-Jun, ATF-2 and Elk-1 can be activated by JNK 
(19).  Moreover,  it  has  been  reported  that  JNK 
pathway  has  a  dual  apoptotic  and  anti-apoptotic 
function (20). Therefore, changes in activation of 
these transcription factors as well as other signaling 
cross talks may be responsible for our observations. 
Furthermore,  the  synergistic  effect  of  etoposide 
treatment and JNK inhibition can be mediated via 
WWOX  activation  and/or  other  pathways  such 
as p53. Since DNA damage induced by etoposide 
utilizes p53 and lack of WWOX protein inhibits p53 
dependent cell death, one can propose shared point(s) 
in JNK and WWOX activation. These shared targets 
can be related to the cell death pathways involved 
in these findings. Clearly, further experiments are 
required to confirm this proposed mechanism.  Taken 
together,  results  of  this  study  provide  evidences 
which can be utilized to decrease etoposide dose in 
patients and increase therapy efficiency in resistant 
cases. It is noteworthy that because of the various 
effects of JNK in cell physiology, JNK inhibitors 
can not be a selective therapeutic choice; however, 
using novel drug delivery systems and/or design of 
selective inhibitors conjugated to etoposide could be 
useful in cancer therapy. 
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